Atomoxetine Treatment of Adults With ADHD and Comorbid Alcohol Abuse

Phase 4CompletedNCT00190957

Eli Lilly and Company140 enrolled

Overview

Atomoxetine Treatment of Adults with ADHD and Comorbid Alcohol Abuse

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

140

Conditions

ADHD Comorbid Alcohol Abuse

Interventions

AtomoxetineDRUG

placeboDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: You must be at least 18 years old. You must have a diagnosis of ADHD and a diagnosis of alcohol abuse or dependence. You must have acceptable results on blood and urine tests and an electrocardiogram (ECG). Your recent drinking history must meet specific requirements. Exclusion Criteria: You have taken atomoxetine in the past. You have a psychiatric disorder, other than ADHD and alcohol abuse or dependence, for which you will need psychiatric medication. You have cognitive impairment (such as memory loss), a brain injury, or a seizure disorder. You have a history of severe allergies to more than 1 class of medication or multiple bad reaction to drugs.

Locations (15)

Outcomes

Primary Outcomes

To test that atomoxetine is superior to placebo in reducing ADHD severity as measured by the Adult ADHD Investigator Symptom Rating Scale (AISRS) Total score and is superior to placebo in time to relapse of alcohol abuse at 12 weeks.

Secondary Outcomes

Total alcohol consumption (mean drinks/day) during the final week of treatment is lower in patients treated with atomoxetine than in patients receiving placebo.

The proportion of drinking days is smaller for atomoxetine-treated patients compared with those in the placebo group.

Time to relapse of alcohol abuse is longer for atomoxetine-treated patients compared with those in the placebo group.

Number of drinks per drinking day is smaller for patients treated with atomoxetine compared with placebo.

The proportion of substance use days, for substances other than alcohol, is smaller among patients treated with atomoxetine as compared with placebo.

After approximately 12 weeks of treatment, patients who receive atomoxetine will have superior social and occupational functioning compared with those who receive placebo as assessed by changes in the EWPS.

Global functioning as assessed by the CGI-Overall-S and the CGI-I are superior in patients treated with atomoxetine as compared with those treated with placebo.

Improvement in depressive symptoms as assessed by the HAM-D-17.

Improvement in anxiety symptoms as assessed by the HAM-A.

Improvement in self-reported ADHD symptoms as assessed by the ASRS.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician

El Centro, California, United States

Poway, California, United States

San Diego, California, United States

New London, Connecticut, United States

Orlando, Florida, United States

Cambridge, Massachusetts, United States

Okemos, Michigan, United States

Columbia, Missouri, United States

Moorestown, New Jersey, United States

New York, New York, United States

...and 5 more locations